WHO global vaccine safety multi-country collaboration project on safety in pregnancy: Assessing the level of diagnostic certainty using standardized case definitions for perinatal and neonatal outcomes and maternal immunization. by Stuurman, Anke L et al.
Vaccine: X 9 (2021) 100123Contents lists available at ScienceDirect
Vaccine: X
journal homepage: www.elsevier .com/locate / jvacxWHO global vaccine safety multi-country collaboration project on safety
in pregnancy: Assessing the level of diagnostic certainty using
standardized case definitions for perinatal and neonatal outcomes and
maternal immunizationhttps://doi.org/10.1016/j.jvacx.2021.100123
2590-1362/ 2021 The Authors. Published by Elsevier Ltd.
This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
⇑ Corresponding author.
E-mail address: maurec@who.int (C. Guillard Maure).
1 WHO GVS MCC sites listed below.
2 Current address: Department of Community Medicine, Kasturba Medical College, Mangalore, Manipal Academy of Higher Education, Manipal, India.Anke L. Stuurman a, Apoorva Sharan b,c,d, Shubhashri Jahagirdar b,1, Varalakshmi Elango a,
Margarita Riera-Montes a, Neeraj Kashyap b, Jorne Biccler a, Ramesh Poluru b, Narendra Arora b,
Matthews Mathai e, Punam Mangtani f, Hugo DeVlieger g, Steven Anderson h, Barbee Whitaker h,
Hui-Lee Wong h, Clare Cutland i, Christine Guillard Maure j,⇑, WHO GVS MCC Sites 2
a P95 Pharmacovigilance and Epidemiology, Leuven, Belgium
b INCLEN Trust International, New Delhi, India
c Swiss Tropical and Public Health Institute (Swiss TPH), Basel, Switzerland
dUniversity of Basel, Basel, Switzerland
eCentre for Maternal and Newborn Health, Liverpool School of Tropical Medicine, Liverpool, UK
fDepartment of Infectious Disease Epidemiology, London School of Tropical Medicine, London, UK
gUniversitair Ziekenhuis, Leuven, Belgium
hCenter for Biologics Evaluation and Research (CBER), U.S. Food and Drug Administration (FDA), Silver Spring, MD, USA
iAfrican Leadership in Vaccinology Expertise (Alive), Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
jDepartment of Regulation and Prequalification, World Health Organisation (WHO) Avenue Appia 20, 1202 Geneva, Switzerlanda r t i c l e i n f o
Article history:
Received 17 June 2021
Received in revised form 31 August 2021
Accepted 29 October 2021








LMICa b s t r a c t
Standardized case definitions strengthen post-marketing safety surveillance of new vaccines by improv-
ing generated data, interpretation and comparability across surveillance systems. The Global Alignment
of Immunization Safety Assessment in Pregnancy (GAIA) project developed standardized case definitions
for 21 key obstetric and neonatal terms following the Brighton Collaboration (BC) methodology.
In this prospective cohort study, we assessed the applicability of GAIA definitions for maternal immu-
nization exposure and for low birth weight (LBW), preterm birth, small for gestational age (SGA), still-
birth, neonatal death, neonatal infection, and congenital microcephaly. We identified the missing data
elements that prevented identified cases and exposures from meeting the case definition (level 1–3 of
BC diagnostic certainty). Over a one-year period (2019–2020), all births occurring in 21 sites (mostly sec-
ondary and tertiary hospitals) in 6 Low Middle Income Countries and 1 High Income Country were
recorded and the 7 perinatal and neonatal outcome cases were identified from routine medical records.
Up to 100 cases per outcome were recruited sequentially from each site.
Most cases recruited for LBW, preterm birth and neonatal death met the GAIA case definitions. Birth
weight, a key parameter for all three outcomes, was routinely recorded at all sites. The definitions for
SGA, stillbirth, neonatal infection (particularly meningitis and respiratory infection) and congenital
microcephaly were found to be less applicable. The main barrier to obtaining higher levels of diagnostic
certainty was the lack of sonographic documentation of gestational age in first or second trimester. The
definition for maternal immunization exposure was applicable, however, the highest level of diagnostic
certainty was only reached at two sites. Improved documentation of maternal immunization will be
important for vaccine safety studies. Following the field-testing of these 8 GAIA definitions, several
improvements are suggested that may lead to their easier implementation, increased standardization
and hence comparison across studies.
 2021 The Authors. Published by Elsevier Ltd. This is an openaccess article under the CCBY license (http://
creativecommons.org/licenses/by/4.0/).
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Immunization during pregnancy can protect the pregnant
woman and her child, both in the womb and in early life by
increasing the antibody titers against vaccine-preventable diseases
[1,2]. Diseases like pertussis, influenza, group B streptococcus
(GBS) infection, respiratory syncytial virus (RSV) infection and
tetanus have a disproportionate impact on the newborn and young
infant. Immunization of pregnant women with Tetanus Toxoid
Containing Vaccine through the Maternal and Neonatal Tetanus
Elimination (MNTE) initiative, achieved elimination of maternal
and neonatal tetanus in 47 countries within twenty years [3]. For
tetanus, immunization in pregnancy is a key strategy to prevent
significant morbidity and mortality amongst young infants glob-
ally. Implementation or strengthening of pertussis and influenza
immunization of pregnant women holds great promise as a strat-
egy to protect infants from these infections [4–6]. This is of specific
interest for Low and Middle-Income Countries (LMICs), where
access to basic health services may be limited and the burden of
vaccine-preventable diseases is large [7].
No evidence of adverse pregnancy outcomes from the vaccina-
tion of pregnant women with inactivated virus, bacterial vaccine,
or toxoid has been found [8]. Live attenuated vaccines pose a the-
oretical risk to the fetus, therefore, these vaccines are generally
contraindicated during pregnancy [9]. However, potential risks of
the vaccine must be balanced against the risk of infection, and in
a recent systematic review no evidence of harm related to live
attenuated vaccines, other than the smallpox vaccine, was found
[10]. Vaccine safety surveillance is complex, especially during
pregnancy, when the risk of adverse outcomes may change due
to underlying maternal health conditions, quality of obstetric care
and the exposure to infection or vaccination during pregnancy [8].
In LMICs, safety monitoring is further challenged by limited phar-
macovigilance infrastructure [11]. Post-marketing safety surveil-
lance of new vaccines used during pregnancy is important for the
detection of any Adverse Events Following Immunization (AEFIs)
in pregnant women and their infants and also to provide informa-
tion on the potential risks to the fetus [8]. This has become very
important now in the context of COVID-19 pandemic, where more
safety data are needed for immunizing this vulnerable group.
Enhancing pharmacovigilance capacity is a strategic goal of the
WHO’s Global Vaccine Safety Blueprint [12]. In this context, the
Global Vaccine Safety Initiative tested the establishment and oper-
ationalization of a global network of hospital-based sentinel sites
for vaccine safety signal verification in the general population
[13]. The present study of safety in pregnancy builds upon lessons
learnt from the earlier proof of concept project [14].
The use of standardized case definitions can strengthen pro-
grams of immunization in pregnancy, by improving generated data
and facilitating data interpretation and comparability across
surveillance systems [15]. To this end, the Global Alignment of
Immunization Safety Assessment in Pregnancy (GAIA) project,
launched in 2015 and managed by the Brighton Collaboration
[16], developed standardized case definitions for 21 key obstetric
and neonatal terms. Within each case definition, multiple ‘Levels
of diagnostic certainty’ are recognized, which take into account
current scientific evidence and different levels of diagnostic capac-
ity available in different research and geographic settings [17].
The primary objective of this prospective study was to assess
the applicability of GAIA definitions for maternal exposure to vac-
cination [18] and for seven perinatal and neonatal outcomes (low
birth weight (LBW) [19], preterm birth [20], small for gestational
age (SGA) [21], stillbirth [22], neonatal death [18], neonatal infec-
tion [23], and congenital microcephaly [24]) in LMICs, in order to
inform future vaccine safety studies. Specifically, we assessed the
proportion of cases or exposures identified that met the GAIA def-2
inition at any level of diagnostic certainty and the proportion that
could be classified to each level. In addition, we identified which
missing data elements prevented identified cases and exposures
from meeting the definition at the lowest level or a higher level
of diagnostic certainty.Methods
This was a prospective, descriptive, cohort study using a com-
mon protocol (S1) and routinely collected data at 21 sites in six
LMICs (Ghana, Tanzania, Zimbabwe, Iran, India, Nepal) and one
high-income country (HIC) (Spain), consisting of one primary care
center, five secondary hospitals and fifteen tertiary hospitals. Each
site had a maternity ward. Sites were selected using a 2017 study
that employed site selection criteria and acceptable performance in
a simulation exercise that tested capacity to access sufficient data
of acceptable quality at the site level [25]. Table 1 lists characteris-
tics of the participating sites. The first site started data collection
on May 6, 2019, and the last site completed data collection on
August 18, 2020. Detailed methods are available in the report [26].
Case identification, recruitment and data collection
All births at the sites were prospectively recorded during a one-
year period, and the following study outcomes occurring in the
28 days following birth were identified as part of routine care by
the sites: LBW, preterm birth, SGA, stillbirth (antepartum or intra-
partum), in-hospital neonatal death, neonatal infection (invasive
bloodstream infection (BSI), respiratory infection or meningitis)
and postnatally diagnosed congenital microcephaly. The outcomes
were selected based on relevance in vaccine safety research and
perceived ability to collect data on the outcome of interest. Cases
were first identified by screening relevant data sources from the
maternity and neonatal wards at the sites (e.g. labor room register,
admission register, patient records; see full list in S2). Only study
outcomes at the site were considered; no follow-up outside of
the site was performed. Estimated rates of occurrence will be
reported in a separate paper and are also accessible in the study
report [26]. At each site, up to 100 cases of each study outcome
were systematically recruited into the study (the first two cases
per week, or all consecutive cases); informed consent was obtained
from the mother. One hundred cases per outcome per site enabled
the calculation of 20% relative precision around estimates of the
proportion of cases meeting the GAIA definition, under the
assumption that 50% of all cases met at least the lowest level def-
inition. Exhaustive case report forms, including details on any vac-
cines received during pregnancy, were completed for recruited
cases, based on existing routine medical records. Data sources
included the mother’s antenatal care records, the antenatal care
card, and inpatient records (full list in S2).
Study site staff were trained on the study procedures. All the
data were captured through an app-based electronic data capture
system, SOMAARTH III [27] using tablets. Data quality was moni-
tored centrally, and on-site monitoring visits and regular tele-
conferences with sites were conducted.
Statistical analysis
We developed algorithms for the GAIA definitions for LBW [19],
preterm birth [20], SGA [21], stillbirth (antepartum and intra-
partum stillbirth) [22], neonatal death [18], neonatal infection
(bloodstream infection (BSI), respiratory infection, meningitis)
[23], postnatally diagnosed congenital microcephaly [24] and
maternal immunization [18] to assess the level of diagnostic cer-
tainty of the GAIA definition met by recruited cases, if any. Cases
Table 1
Characteristics of participating sites.








Number of births during the
one-year study period, n
AFRO
Ghana St Joseph’s H Secondary Public Yes Paper 1634
Ghana Ejisu H Secondary Public Yes Paper 1442
Ghana Tema GH Secondary Public Yes Paper 5523
Ghana Eastern RH Secondary Public Yes Combination 5387
Tanzania Mbeya ZRH Tertiary Public No Combination 7023
Tanzania St Francis RH Tertiary Public Private Partnership No Paper 3484
Tanzania Mbeya RRH Tertiary Public Yes Paper 3930
Zimbabwe Mbare PC Primary Public No Paper 5501
Zimbabwe Mutare PH Tertiary Public No Paper 1558
EMRO
Iran Mahdieh H Tertiary Public Yes Combination 5802
Iran Shohada TH Tertiary Public Yes Combination 864
EURO
Spain General Castellon UH Tertiary Public Yes Electronic 1390
Spain Dr Peset UH Secondary Public No Electronic 1078
SEARO
India JSS H Tertiary Private Yes Combination 2796
India Grant GMC Tertiary Public Yes Paper 2251*
India IMS SUM H Tertiary Private Yes Combination 1805
India Kasturba MC Tertiary Private Yes Combination 2762
India MP Shah MC Tertiary Public Yes Paper 9996
India SKIMS Tertiary Public Yes Paper 3188
Nepal Patan H Tertiary Public Yes Paper 7573
Nepal BP Koirala Tertiary Public Yes Combination 10,554
*8 months instead of 1 year at Grant GMC.
AFRO: WHO African region; BP: BP Koirala Institute of Health Sciences; EMRO: WHO Eastern Mediterranean region; EURO: WHO European region; GH: General Hospital;
GMC: Government Medical College; GUH: General University Hospital; H: Hospital; IMS SUM: Institute of Medical Science and Sum Hospital; MC: Medical College; NICU:
neonatal intensive care unit; PC: Policlinic; PH: Provincial Hospital; RH: Referral/Regional Hospital; RRH: Regional Referral Hospital; SEARO: WHO South-East Asia region;
SKIMS: Sher-i-Kashmir Institute of Medical Sciences; TH: Teaching Hospital; UH: University Hospital; ZRH: Zonal Referral Hospital.
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Level 1 represented the highest levels of diagnostic certainty (most
specific, least sensitive), and Level 3 the lowest (least specific, most
sensitive). Levels 4 and 5, if present, were not considered as those
events did not meet the case definition. The GAIA definitions have
been summarized in S3a. First, it assessed whether Level 1 criteria
were met. If yes, then the case was considered classified to Level 1.
If no, it assessed whether Level 2 criteria were met, and so on. For
each definition, the applicability was assessed by calculating the
proportion of cases or maternal immunization exposures meeting
the GAIA definition and the proportion classified to each level, by
site. The most common reasons for not meeting GAIA definitions
or, for non-classification of level 3 cases to levels 1–2 were summa-
rized (or described) for each outcome.
We modified the GAIA definition so that criteria accepted at
higher levels of diagnostic certainty (‘higher levels of evidence’)
were also de facto acceptable at lower levels of diagnostic certainty.
For example, in the case of LBW, we considered electronic scales
(sufficient for levels 1 and 2) appropriate for a level 3 classification
as well (S3b for further details). Several aspects of the maternal
immunization definition were open to interpretation. For level 1,
we interpreted ‘date/time’ as ‘date AND time’ and ‘details of vac-
cine’ as ‘lot number AND EITHER name of disease OR name of vac-
cine’. For level 2, we interpreted ‘details of disease’ as ‘name of the
disease OR name of vaccine OR lot number’. For levels 1–2, primary
sources such as the antenatal care card, vaccine card or vaccine reg-
ister were required, and for level 3, secondary sources were
accepted such as the patient case sheet or birth register.
For each outcome, the proportion of recruited cases that met
the GAIA definition was stratified by country, health facility level
(primary, secondary, tertiary/referral), and health facility owner-
ship (public/private). A Chi-square test was used to assess whether
there were any significant differences between the categories.3
Double independent programming of all analyses was per-
formed using R version 3.6.0 [28] by the company, P95 Epidemiol-
ogy and Pharmacovigilance and Stata version 15.1 [29] by INCLEN
Trust International. Output was compared and the differences
were resolved.Ethics approval
The study was approved by the WHO Ethics Review Committee
(protocol ID: ERC.0003114), and by local and national committees
as appropriate [26].Results
Table 2 shows the number of cases recruited for each outcome
by site. The number of cases recruited was highest for LBW and
preterm birth, and lowest for meningitis, respiratory infection
and congenital microcephaly. Table 3 shows exposure to (any) vac-
cination during pregnancy for each site. The median percentage of
mothers identified by the sites as vaccinated during pregnancy was
82.4% (interquartile range (IQR): 61.2–88%); the exposure status
was reported as unknown for 16.2% (median) of mothers (IQR:
5.6–31.7%).
The site-specific percentage of cases or exposures that met the
GAIA definition and, among those, the percentage that were classi-
fied to levels 1–3 have been summarized for all study outcomes in
Fig. 1. Further, median and site-specific results are also available in
S4. Differences in percentage of cases meeting the case definition
by country, health facility level and public vs private ownership
are available in the report [26].
LBW: Nearly 100% of recruited cases with LBW across the sites
met the case definition (median: 100%; IQR: 100–100%). At most
Table 2
Number of cases recruited for each outcome by site.
Cases recruited, n






Antepartum Intrapartum BSI Meningitis Respiratory
infection
AFRO
Ghana St Joseph’s H 100 88 82 16 13 25 63 0 12 2
Ghana Ejisu H 59 27 18 5 7 0 15 0 0 1
Ghana Tema GH 101 100 99 6 93 63 61 0 6 3
Ghana Eastern RH 101 100 100 93 7 95 49 3 0 2
Tanzania Mbeya ZRH 109 95 83 81 21 83 23 2 2 1
Tanzania St Francis RH 100 98 - * 51 46 63 65 4 4 - *
Tanzania Mbeya RRH 100 97 99 57 29 59 79 2 2 3
Zimbabwe Mbare PC 106 76 74 3 8 8 8 0 0 0
Zimbabwe Mutare PH 101 99 86 40 10 66 6 0 1 0
EMRO
Iran Mahdieh H 100 100 102 77 9 69 50 0 11 28




104 100 57 NA NA 3 7 1 NA 11
Spain Dr Peset UH 47 45 48 NA NA 0 7 0 NA 14
SEARO
India JSS H 100 99 85 10 11 14 53 2 5 9
India Grant GMC 98 96 24 34 16 28 4 2 0 0
India IMS SUM H 100 99 98 58 NA 7 24 3 0 6
India Kasturba MC 101 100 100 29 4 28 59 3 2 11
India MP Shah MC 118 97 91 70 23 52 61 1 11 3
India SKIMS 100 101 34 35 8 32 34 0 NA 1
Nepal Patan H 101 101 66 35 5 15 15 22 65 3
Nepal BP Koirala 131 104 105 88 12 27 54 11 29 15
Total 2050 1914 1467 807 326 751 783 57 155 120
More than 100 cases at some sites were due to overlapping case definition requirements.
* SGA and congenital microcephaly are not routinely diagnosed at St Francis RH.
AFRO:WHO African region; BP: BP Koirala Institute of Health Sciences; BSI: bloodstream infection; EMRO: WHO Eastern Mediterranean region; EURO:WHO European region;
GH: General Hospital; GMC: Government Medical College; GUH: General University Hospital; H: Hospital; IMS SUM: Institute of Medical Science and Sum Hospital; MC:
Medical College; NA: Not applicable; NICU: neonatal intensive care unit; PC: Policlinic; PH: Provincial Hospital; RH: Referral/Regional Hospital; RI: respiratory infection; RRH:
Regional Referral Hospital; SEARO: WHO South-East Asia region; SKIMS: Sher-i-Kashmir Institute of Medical Sciences; TH: Teaching Hospital; UH: University Hospital; ZRH:
Zonal Referral Hospital.
Table 3
Number of mothers assessed for exposure to (any) vaccination during pregnancy, by site.
Country Site Exposure to vaccination assessed, n Exposed, n (%) Unexposed, n (%) Exposure unknown, n (%)
AFRO
Ghana St Joseph’s H 284 250 (88) 27 (9.5) 7 (2.5)
Ghana Ejisu H 94 60 (63.8) 13 (13.8) 21 (22.3)
Ghana Tema GH 425 78 (18.4) 12 (2.8) 335 (78.8)
Ghana Eastern RH 428 306 (71.5) 65 (15.2) 57 (13.3)
Tanzania Mbeya ZRH 375 67 (17.9) 6 (1.6) 302 (80.5)
Tanzania St Francis RH 343 210 (61.2) 56 (16.3) 77 (22.4)
Tanzania Mbeya RRH 386 329 (85.2) 30 (7.8) 27 (7)
Zimbabwe Mbare PC 183 106 (57.9) 19 (10.4) 58 (31.7)
Zimbabwe Mutare PH 253 211 (83.4) 26 (10.3) 16 (6.3)
EMRO
Iran Mahdieh H 402 17 (4.2) 45 (11.2) 340 (84.6)
Iran Shohada TH 188 0 (0) 128 (68.1) 60 (31.9)
EURO
Spain General Castellon UH 161 138 (85.7) 14 (8.7) 9 (5.6)
Spain Dr Peset UH 86 76 (88.4) 4 (4.7) 6 (7)
SEARO
India JSS H 255 196 (76.9) 4 (1.6) 55 (21.6)
India Grant GMC 204 168 (82.4) 3 (1.5) 33 (16.2)
India IMS SUM H 270 268 (99.3) 2 (0.7) 0 (0)
India Kasturba MC 285 235 (82.5) 0 (0) 50 (17.5)
India MP Shah MC 436 412 (94.5) 10 (2.3) 14 (3.2)
India SKIMS 271 263 (97) 7 (2.6) 1 (0.4)
Nepal Patan H 298 193 (64.8) 0 (0) 105 (35.2)
Nepal BP Koirala 373 370 (99.2) 2 (0.5) 1 (0.3)
AFRO: WHO African region; BP: BP Koirala Institute of Health Sciences; EMRO: WHO Eastern Mediterranean region; EURO: WHO European region; GH: General Hospital;
GMC: Government Medical College; GUH: General University Hospital; H: Hospital; IMS SUM: Institute of Medical Science and Sum Hospital; MC: Medical College; NICU:
neonatal intensive care unit; PC: Policlinic; PH: Provincial Hospital; RH: Referral/Regional Hospital; RRH: Regional Referral Hospital; SEARO: WHO South-East Asia region;
SKIMS: Sher-i-Kashmir Institute of Medical Sciences; TH: Teaching Hospital; UH: University Hospital; ZRH: Zonal Referral Hospital.
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Fig. 1. Applicability of GAIA definitions at the study sites. Study sites are represented by dots (column 1) and circles (columns 2–4). Column 1 (‘meets definition’) shows, for
each outcome, the distribution of the percentage of recruited cases (or, for maternal immunization, identified exposures) that met the GAIA definition across the sites.
Columns 2–4 show the distribution of the percentage of cases classified at level 1 (most specific), 2, and 3 (least specific), among cases that met the GAIA definition across the
sites. For each individual site, columns 2–4 sum to 100%. The darker the circle, the larger the number of sites.
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diagnostic certainty due to the standard operating procedures for
birthweight measurements at the sites.
Preterm birth: All recruited preterm birth cases met the GAIA
definition. At most sites, classified cases were spread over the three
levels of diagnostic certainty. At least 10% of the cases at each site
were classified at level 3.
SGA: The percentage of SGA cases that met the GAIA definition
varied widely among the sites (median: 63.5%, IQR: 0–79%). At
six sites (out of 20, one site did not routinely diagnose SGA) no
cases met the definition. The majority of the classified cases were
classified to either level 2 or 3.
Stillbirth: Stillbirths were recruited at all sites, except for one
site in Spain where no stillbirths were observed during the study
period. At all but two sites part of the recruited stillbirth cases
met the GAIA definition; all sites had cases that did not meet the
GAIA definition. The median percentage of stillbirth cases that
met the GAIA definition across sites was 66.7% (IQR: 45–89%) for
antepartum and 37.3% (IQR: 25–58%) for intrapartum stillbirths.
Most classified antepartum stillbirths were classified as level 1 or
level 3 and the majority of intrapartum stillbirths were classified
as level 3.
Neonatal Death: Nearly all recruited neonatal death cases met
the GAIA definition (median: 100%; IQR: 100–100%). All but one
of the classified cases were classified as Level 1. A single case
was classified as level 3.
Neonatal Infection: At all but one site, part of the neonatal infec-
tion cases met the GAIA definition. All sites recruited BSI cases. The
median percentage of recruited BSI cases that met the GAIA defini-
tion across sites was 93% (IQR: 57–98%). At one site no cases met
the GAIA definition. Level 1 was reached for some of the cases at
11 sites. At 16 sites, most classified cases were of level 2. Thirteen
sites recruited meningitis cases, less than a quarter of all cases met
the GAIA definition (median across sites 0%; IQR: 0–33%). Two
cases were classified to level 1, four to level 2 and nine cases to
level 3; 49 cases were not classified. Thirteen sites recruited cases
of neonatal respiratory infection, the median percentage of cases
that met the GAIA definition across sites was 100 % (IQR: 83–
100%). Most classified cases were classified to level 3.5
Congenital Microcephaly: Seventeen sites (out of 20, one site did
not routinely diagnose congenital microcephaly) recruited cases of
congenital microcephaly. At five of these sites none of the cases
met the GAIA definition. The median percentage of recruited con-
genital microcephaly cases that met the case definition was 67%
(IQR: 0–93%). Most cases were classified to level 2, with fewer
cases meeting level 1 or 3.
Maternal immunization: The percentage of identified maternal
immunization exposures that were classified using the GAIA defi-
nition was close to 100%. The majority of exposures were classified
at levels 2 and 3, level 1 was reached by two sites.
Reasons for not meeting levels of diagnostic certainty
The reasons for not meeting the GAIA definition to at least level
3 (least specific) were definition-specific (the most frequent rea-
sons are summarized in Table 4, full details are available in S4).
A recurrent limiting factor for level 3 cases not meeting levels 1–
2 was the GA assessment, particularly that no or insufficient infor-
mation on 1st or 2nd trimester ultrasound was available. For
maternal immunization, the most important reason for not meet-
ing levels 1–2 was the absence of a primary source documenting
vaccine exposure during pregnancy, such as the antenatal card or
a vaccine card.
Discussion
Applicability of GAIA definitions
In this study, the applicability of GAIA definitions for seven peri-
natal and neonatal outcomes and for maternal immunization were
assessed using routinely collected data, primarily at tertiary level
referral hospitals. The definitions for LBW [19], preterm birth
[20], and neonatal death [18] were applicable at the study sites,
as nearly all cases recruited by the sites met the GAIA definitions.
For neonatal death, nearly all cases met the criteria for level 1 of
diagnostic certainty. Birth weight (BW), a key parameter for all
the three outcomes, was routinely measured and recorded at all
the sites, contributing to the applicability of these case definitions.
Table 4
Most frequent reasons for not meeting level 3 (among cases not meeting the GAIA
definition) and for level 3 cases not meeting levels 1 and 2.
Not meeting the GAIA
definition (at level 3)
Not meeting levels 1 and 2
Low birth
weight
NA* Unknown or inappropriate
graduation or calibration of
the scale
Preterm birth NA No or insufficient





The weight was over the
10th percentile for GA on the
Intergrowth-21 charts
GA criteria not met (No or
insufficient information on
1st or 2nd trimester
ultrasound)
Stillbirth No recorded data on absence
or presence of fetal signs of
life prior to the onset of
labour
GA criteria not met (No or
insufficient information on
1st or 2nd trimester
ultrasound)










NA* Birth weight not available
and although an estimate of
GA was available, GA criteria
not met
Neonatal bloodstream infection Insufficient clinical criteria
met













Fever criterion not met and
an insufficient number of
other clinical criteria met
Negative (no pathogen
identified in the sample) or
insufficient findings from a
sample tested from CSF or




GA: gestational age; LMP: Last Menstrual Period; NA: not applicable.
*Unresolved queries sent to the site (n = 2 for low birth weight, n = 2 for neonatal
death).
**Exposure did not meet the GAIA definition due to a mistake in the design of the
case report form (n = 24; 0.6% of exposures assessed).
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nition using both prospective and retrospective data [30]. A signif-
icant proportion of cases of stillbirth [22], SGA [21], congenital
microcephaly [24] and neonatal infection [23] (particularly menin-
gitis) did not meet the GAIA definitions, hence these definitions
were less applicable at the study sites. This study also gave insight
into site-specific levels of diagnostic certainty and pinpointed
aspects preventing higher levels of diagnostic certainty from being
met, both of which will help inform the design of future vaccine
safety studies in pregnancy. The main barrier to obtaining higher
levels of diagnostic certainty (for all outcomes except low birth
weight, neonatal infection and maternal immunization) was the
lack of/ no access to sonographic documentation in first and second
trimester and its impact on GA assessment. Better clinical record
keeping or documentation of GA in the early stages of pregnancy
as part of routine care across caregivers would improve assessment
of outcomes requiring GA. In this study, we evaluated how certain
we were that a case diagnosed by a site was truly a case; one lim-
itation is that we did not assess how certain we were an outcome
was truly absent if not diagnosed. This was not possible as the
study was records-based.6
The definition for maternal immunization [18] was applicable
at the study sites. However, at 5 out of 21 sites, most exposures
were classified to level 3, for which no formal documentation of
the vaccination is required. The usefulness of level 3 may be lim-
ited in vaccine safety surveillance and studies due to the sparsity
of information on vaccination. Level 1 was achieved at only two
sites, which routinely collected the batch number for vaccines
administered as part of antenatal care in their facility. Not all ele-
ments of level 1 are necessarily required when studying neonatal
outcomes in the context of maternal immunization safety, such
as time (hour) of vaccination and batch number. Whereas level 2
does not require the exact date of vaccination (only month and
year), however, this information is key to understanding vaccine
safety at different stages of fetal development. In the study, due
to a mistake in the design of the case report form, 0.6% of identified
exposures could not be classified. If the site indicated that the
number of doses was not known, the question on data sources
was not prompted and therefore not completed, preventing classi-
fication to any level. If the number of doses was not known it is
likely the source was secondary, which would have enabled classi-
fication to Level 3.
Information on maternal immunization was collected from doc-
uments available at the sites at the time of case recruitment, fre-
quently the antenatal care card (often allowing to reach level 2
of certainty), or at some sites, the patient record (e.g., whether vac-
cination was done as per recommendation, often enabling classifi-
cation only to level 3); no interview with the mother was
conducted as part of the study. Furthermore, the antenatal care
card belonged to the mother and was normally not available
post-discharge. Vaccine exposure status for some mothers was
unknown, which might have resulted in missed exposures. Had
interviews been conducted, the number of exposures classified to
level 3 (instead of unknown) would likely have been higher. More
intensive efforts and outreach may be critical for retrieval of infor-
mation on vaccination status and details of the vaccination. As dif-
ferent COVID19 vaccines are being deployed worldwide and may
be used alternatively or simultaneously in each country, the rigor-
ous recording of vaccination exposure in pregnant women is of
paramount importance to enable safety monitoring. Advocacy with
health program managers and policy makers is needed for
improved documentation and inclusion of additional fields vital
for maternal immunization pharmacovigilance in the antenatal
care card, and increased digitization could enhance reporting and
utilizing immunization data in the context of vaccine safety.
We assessed whether the percentage of cases meeting the GAIA
definition differed by country, health facility level and public vs
private ownership. However, as sites were not selected to be rep-
resentative of these categories and due to low number of sites in
each stratification, we do not feel confident that any differences
observed can be meaningfully extrapolated beyond this study.
Challenges in using the GAIA definitions
Based on our experiences in field-testing the GAIA definitions,
we have suggested several improvements to the GAIA definitions
that may lead to their easier implementation and increased stan-
dardization across studies.
Accepting higher levels of evidence at lower levels of diagnostic cer-
tainty: In the study, we accepted higher levels of evidence at lower
levels of diagnostic certainty to prevent cases from ‘‘falling in
between”different levels and consequentlynot being classified. This
has been previously documented for the stillbirth definition [25,30]
butweobserved the similar issues in the LBW, SGA, neonatalmenin-
gitis and maternal immunization definitions (details in S3b).
Consistency of GA and BW information: The requirements for GA
or BW are not identical across all case definitions. The GA assess-
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death and SGA. However, the GA criteria for congenital micro-
cephaly differ, and are at times more stringent (level 1a necessi-
tates LMP, level 2a does not allow for 1st trimester physical
exam, level 3a necessitates LMP and does not allow for other mea-
sures such as BW) and sometimes, more lenient (level 1a allows for
second trimester ultrasound scan). In addition, for neonatal death
level 1, either GA level 1 or BW is necessary for classification, how-
ever if GA were assessed using BW it would result in GA level 3.
BW requirements in the LBW case definition were based on the
details regarding timing of the measurement and scale specifica-
tions. The criteria listed in the SGA case definition differs for SGA
level 3, where scale specifications for SGA level 3a are more strin-
gent (resolution of less than 50 g, tared to zero, calibrated) than in
the LBW case definition. Furthermore, for the case definitions for
neonatal death and preterm birth, no requirements are attached
to the BW assessment.
Several other areas of improvement were identified in the
maternal immunization (interpretation; see methods section),
neonatal death (viability/maturity), stillbirth (GA, signs of life,
combination of criteria), congenital microcephaly (chart use) and
SGA definitions (S3c).
More countries are adopting policy recommendations for
COVID-19 vaccination in pregnant women, based on WHO’s
interim recommendations to use COVID-19 vaccines during preg-
nancy, when the benefits outweigh potential risks. As pregnant
women were excluded from clinical trials, safety profile of
COVID-19 vaccines will need to be evaluated from post marketing
safety data. In this context, it is of critical importance to ensure
harmonisation of terminologies, definitions, and methods of
assessment to allow comparability and timely assessment through
meta-analysis of data collected worldwide.
Conclusion
This prospective study showed that the GAIA definitions for
LBW, preterm birth, neonatal death and maternal immunization
when vaccination was noted were applicable at the study sites,
however, the ones for stillbirth, SGA, neonatal infections and con-
genital microcephaly were less so. The level of diagnostic certainty
of GA was identified as a limiting factor to attaining higher levels of
diagnostic certainty for multiple outcomes and several areas of
improvement have been suggested following field-testing of the
definitions. The introduction of COVID-19 vaccines, and their pos-
sible use in pregnant women, reinforces the urgency for improved
documentation of vaccination and outcomes vital for maternal
immunization pharmacovigilance.
WHO GVS MCC Sites
Ghana
Joseph HK Donkor, Tema General Hospital, Tema, Ghana.
Richard Wodah-Seme, St. Joseph’s Hospital, Jirapa, Ghana.
Kwasi Baffour Gyimah, Ghana Health Service: Ejisu Government
Hospital, Ejisu, Ghana.
Seth Twum, Eastern Regional Hospital, Ghana.
Tanzania
Issa Sabi, National Institute for Medical Research (NIMR),
Mbeya Medical Research Center, Mbeya, Tanzania.
Rebecca Mokeha, Mbeya Zonal Referral Hospital, Mbeya,
Tanzania.7
Elias Kweyamba and Henry Marique, St. Francis Referral Hospi-
tal, Ifakara, Tanzania.
Ismail Macha, Mbeya Regional Referral Hospital, Mbeya,
Tanzania.
Zimbabwe
Jaensch Masanga Mutede, Mutare Provincial Hospital, Ministry
of Health and Child Care, Zimbabwe.
Prosper Chonzi, City of Harare, Health Department, Ministry of
Health and Child Care (for Mbare Provincial Hospital),
Zimbabwe.
Iran
Maryam Shariati and Elahe Rastkar Mehrabani, Clinical
Research Development Center, Mahdiyeh Educational hospital,
Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Spain
Alejandro Orrico-Sánchez, Antonio Carmona and Dafina Pet-
rova, Vaccine Research Department, Fundación para el Fomento
de la Investigación Sanitaria y Biomédica de la Comunitat
Valenciana, FISABIO-Public Health, Valencia, Spain.
India
Javeed Iqbal Bhat, Bashir Ahmad Charoo and Rabia Khurshid
Department of Pediatrics, Sher-i-Kashmir Institute of Medical
Sciences Srinagar Jammu & Kashmir, India.
Leslie Lewis, Muralidhar Pai, Shyamla G, Jyothi Shetty, Akhila
Hebbar, Sripad Hebbar and Prathap Kumar, Kasturba Medical
College, Manipal Academy of Higher Education, Manipal, India.
Bhadresh R Vyas, MP Shah Government Medical College, Jamna-
gar, India.
Lalit Sankhe, Department of Community Medicine, Grant Med-
ical College, Mumbai, India.
Rachita Sarangi and Jagdish Prasad Sahoo, Indian Institute of
Medical Sciences and SUM hospital, Bhubaneswar, Orissa, India.
M D Ravi and H V Prajwala, JSS Academy of Higher Education
and Research, Mysuru, Karnataka, India.
Nepal
Nisha Keshary Bhatta, Shyam Prasad Kafle, Mukesh Bhatta and
Mohan Chandra Regmi, B.P.Koirala Institute of Health Sciences,
Dharan, Nepal.
Prerana Kansakar and Ganesh Shah, Department of Pediatrics,
Patan Academy of Health Sciences, Nepal.
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